2nd Oct 2012 14:02
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.
On 28 September 2012, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £14.37 per Ordinary Share, and notional ADSs at a price of $46.52 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2012 to 30 September 2012:
Non Executive Director | Ordinary Shares | American Depositary Shares (ADSs) |
Sir Christopher Gent | 2,348.643 | |
Professor Sir Roy Anderson | 456.681 | |
Dr Stephanie Burns | 443.463 | |
Stacey Cartwright | 326.200 | |
Sir Crispin Davis | 1,652.749 | |
Lynn Elsenhans | 570.166 | |
Judy Lewent | 221.731 | |
Sir Deryck Maughan | 886.925 | |
Dr Daniel Podolsky | 855.249 | |
Tom de Swaan | 674.148 | |
Jing Ulrich | 158.379 | |
Sir Robert Wilson | 456.681 |
The Company and the Non-Executive Directors were informed of these allocations on 1 October 2012.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
2 October 2012
Related Shares:
Glaxosmithkline